Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 70M | 0 | 0 | 0 | 0 |
| Gross Profit | 70M | 0 | -437K | 0 | 0 |
| Operating Income | 20M | -79M | -86M | -93M | -127M |
| EBITDA | 20M | -78M | -86M | -92M | -127M |
| Net Income | 22M | -70M | -82M | -91M | -126M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.69
-9.14% today
1Y Change
-35.91%
Window
Jun 25, 2025 → Jun 18, 2026
Coverage: 247 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Black Diamond Therapeutics, Inc. (BDTX) is a Healthcare stock with a market cap of $160.00M. The stock last traded around $1.69 and down 35.9% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +130.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +130.7%, free cash flow +147.5% with operating margin 28.4% and ROIC 15.6%. Valuation is more restrained than many high-expectation growth names at P/E 7.3 and price/sales 2.3. Stock Foundry combines BDTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BDTX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BDTX Max Drawdown
-65.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BDTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$125.6M
-37.8% YoY
Free Cash Flow
-$102.9M
-20.6% YoY
Revenue Growth
+0.0%
EPS Growth
+130.7%
Gross Margin
99.8%
Net Margin
32.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 70M | 0 | 0 | 0 | 0 |
| Gross Profit | 70M | 0 | -437K | 0 | 0 |
| Operating Income | 20M | -79M | -86M | -93M | -127M |
| EBITDA | 20M | -78M | -86M | -92M | -127M |
| Net Income | 22M | -70M | -82M | -91M | -126M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 36M | 56M | 34M | 66M |
| Total Assets | 143M | 123M | 159M | 156M | 248M |
| Total Liabilities | 31M | 39M | 42M | 41M | 52M |
| Shareholder Equity | 112M | 83M | 117M | 116M | 196M |
| Total Debt | 15M | 22M | 25M | 28M | 28M |
| Net Debt | -6M | -14M | -31M | -6M | -37M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
100M
-17.7% YoY
Capital Expenditures
3M
-1311.5% YoY
Free Cash Flow
103M
-20.6% YoY
Key ratios
Gross Margin
99.8%
Operating Margin
28.4%
Net Margin
32.0%
ROE
17.5%
Debt / Equity
0.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.